<SEC-DOCUMENT>0001171843-20-003810.txt : 20200518
<SEC-HEADER>0001171843-20-003810.hdr.sgml : 20200518
<ACCEPTANCE-DATETIME>20200518165348
ACCESSION NUMBER:		0001171843-20-003810
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200518
FILED AS OF DATE:		20200518
DATE AS OF CHANGE:		20200518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		20890357

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_051820.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report: May 18, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-38844 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENFIT S.A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name
into English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>59120 Loos, France</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; text-align: left">&#9746; Form 20-F</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">&#9744; Form 40-F</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT LIST </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated May 18, 2020.</FONT></A></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 18, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27.95pt; text-align: center; color: #005478"><FONT STYLE="font-size: 14pt"><B>GENFIT:
Reports First Quarter 2020 Financial Information</B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 27.95pt 0pt 27.8pt; text-align: center; color: #005478"><FONT STYLE="font-size: 12pt">(Unaudited
financial information under IFRS)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol; font-weight: normal">-</FONT></TD><TD>Cash and cash equivalents totaled &euro;252 million as of March 31, 2020</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 23.85pt; text-align: right"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">-</font></TD><TD STYLE="text-align: justify"><B>Additional information regarding implications of interim analysis of top-line RESOLVE-IT
data</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.9pt; text-align: justify"><FONT STYLE="color: #005278"><B>Lille
(France), Cambridge (Massachusetts, United States), May 18, 2020 </B></FONT><B>&ndash; GENFIT (Nasdaq and Euronext: GNFT)</B>,
a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced
its cash position as of March 31, 2020 and revenues for the first three months of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005278">Cash position</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.9pt; text-align: justify">As of March 31, 2020, the
Company&rsquo;s cash and cash equivalents amounted to &euro;252.0 million compared with &euro;314.1 million as of March 31, 2019
and &euro;276.7 million as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005278">Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">Revenues for the first three
months of 2020 amounted to &euro;102 thousand compared to &euro;1 thousand for the same period in 2019. Revenues mainly consisted
of revenues from services provided to Terns Pharmaceuticals pursuant to the collaboration and license agreement in relation to
their clinical trials.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005278">Additional Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5.9pt; text-align: justify">Following the May 11, 2020
announcement of the interim results from the RESOLVE-IT Phase 3 clinical trial evaluating elafibranor in adults with NASH and fibrosis,
GENFIT outlines the main operational and financial implications of this announcement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">Operational implications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.9pt; text-align: justify">Elafibranor did not show
a statistically significant effect on the primary endpoint of NASH resolution without worsening of fibrosis, and therefore the
top-line results do not support an application for accelerated approval by the FDA (U.S. Food and Drug Administration) under Subpart
H or conditional approval by the EMA (European Medicines Agency).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.9pt; text-align: justify">However, before taking a
final decision regarding the discontinuation, amendment or continuation of the RESOLVE-IT trial, GENFIT will review in detail the
full dataset and will conduct additional analyses in order to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.9pt"></TD><TD STYLE="width: 18pt">-</TD><TD STYLE="padding-right: 6.45pt">Understand why the placebo response rate was higher than what was observed in other late stage
clinical trials using similar protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-size: 10pt"><B>GENFIT </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.85pt"></TD><TD STYLE="width: 18.05pt">-</TD><TD>Determine whether there is still a potential for elafibranor in specific subpopulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.9pt; text-align: justify">GENFIT will then engage
with the FDA and the EMA, and will take a decision regarding the discontinuation, amendment or continuation of the RESOLVE-IT trial
following its discussions with regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.7pt 0pt 5.9pt; text-align: justify">GENFIT remains fully committed
to developing NIS4<FONT STYLE="font-family: Times New Roman, Times, Serif">&trade;, </FONT>its non-invasive diagnostic technology,
to identify at-risk NASH patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 5.9pt; text-align: justify">With regards to PBC (Primary
Biliary Cholangitis), given elafibranor&rsquo;s activity in Phase 2, and its safety profile confirmed by the RESOLVE-IT interim
data, and because PBC is an autoimmune disease unrelated to the metabolic origins of NASH, GENFIT is confident in its Phase 3 development
program evaluating elafibranor in this indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 5.9pt; text-align: justify">Finally, GENFIT remains open
to opportunities that could create value for the Company, whether through forging new strategic partnerships or new scientific
collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify">GENFIT plans to share its
updated corporate strategy in the Fall 2020, once a decision regarding the RESOLVE-IT trial is taken, including potential decisions
regarding its product pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify">Financial implications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.9pt"></TD><TD STYLE="width: 18pt">-</TD><TD STYLE="padding-right: 5.85pt">GENFIT is reviewing all non-essential expenses and a first series of measures includes terminating
all marketing and commercialization readiness activities for elafibranor in NASH.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.9pt"></TD><TD STYLE="width: 18pt">-</TD><TD STYLE="padding-right: 5.75pt">However, since no immediate decision can be taken regarding the future of the RESOLVE-IT trial,
the trial will continue and its associated costs will continue , including those related to:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD>Contract Research Organization activities; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59.9pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="padding-right: 5.75pt">patient monitoring, which cannot be interrupted abruptly due to ethical and regulatory concerns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5.9pt; text-align: justify">In the event a decision is
taken to discontinue the RESOLVE-IT trial in the Fall 2020, given the size and complexity of the study, residual costs are to be
expected and the full impact of the decision on the Company&rsquo;s cash burn will not be noticeable until several months following
the termination of the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: justify; color: #005478">ABOUT GENFIT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt; text-align: justify">GENFIT is a late-stage biopharmaceutical
company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in
the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades.
Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial (&ldquo;RESOLVE-IT&rdquo;)
as a potential treatment for NASH and GENFIT plans to initiate a Phase 3 clinical trial of elafibranor in patients with PBC. As
part of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-size: 10pt"><B>GENFIT </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.8pt 0pt 5.9pt; text-align: justify">GENFIT&rsquo;s comprehensive
approach to clinical management of patients with NASH, the Company is also developing a new, non-invasive blood-based diagnostic
test, NIS4&trade;, which, if approved, could enable easier identification of patients with NASH. With facilities in Lille and
Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company listed
on the Nasdaq Global Select Market and on compartment B of Euronext&rsquo;s regulated market in Paris (Nasdaq and Euronext: GNFT).
www.genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005478">FORWARD LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 5.9pt; text-align: justify">This press release contains
certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995,
with respect to GENFIT, including statements regarding our expected future performance, business prospects, financial perspective,
corporate strategy, events and plans, including timing of further analyses and the publication of the full data set of the interim
results of our Phase 3 RESOLVE-IT clinical trial, our expected clinical and regulatory strategy for elafibranor, discussions with
regulatory authorities regarding RESOLVE-IT, the impacts of decisions surrounding the future of the RESOLVE-IT trial on our cash
position, and the timing of clinical and regulatory milestones in our PBC and NIS4 programs. The use of certain words, including
&ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;expect&rdquo; and &ldquo;will&rdquo; and similar expressions, is intended
to identify forward- looking statements. Although the Company believes its expectations are based on the current expectations and
reasonable assumptions of the Company&rsquo;s management, these forward-looking statements are subject to numerous known and unknown
risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected
by, the forward- looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research
and development, including related to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials,
review and approvals by regulatory authorities of its drug and diagnostic candidates and the Company&rsquo;s continued ability
to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company&rsquo;s
public filings with the French Autorit&eacute; des march&eacute;s financiers (&ldquo;AMF&rdquo;), including those listed in Section
4 &ldquo;Main Risks and Uncertainties&rdquo; of the Company&rsquo;s 2018 Registration Document filed with the AMF on February 27,
2019 under n&deg; D.19-0078, which is available on GENFIT&rsquo;s website (www.genfit.com) and on the website of the AMF (www.amf-france.org)
and public filings and reports filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;), including the Company&rsquo;s
final prospectus dated March 26, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public,
by the Company. In addition, even if the Company&rsquo;s results, performance, financial condition and liquidity, and the development
of the industry in which it operates are consistent with such forward- looking statements, they may not be predictive of results
or developments in future periods. These forward-looking statements speak only as of the date of publication of this document.
Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking
information or statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-size: 10pt"><B>GENFIT </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; color: #005478">CONTACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><B>GENFIT </B>| Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">Naomi EICHENBAUM &ndash; Investor Relations | Tel:
+1 (617) 714 5252 | investors@genfit.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt"><B>PRESS RELATIONS </B>| Media</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">H&eacute;l&egrave;ne LAVIN &ndash; Press relations
| Tel: +333 2016 4000 | helene.lavin@genfit.com</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-size: 10pt"><B>GENFIT
                           </B>| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P>



</TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" P\# 2(  A$! Q$!_\0
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M':=AAIWW#_=' _K7GY-!RQ::Z79Z.:34<,T^MC:N[RWT^SEN[J58H(E+N[=
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M#I__ (,F_P#C5.^W^*?^@#I__@S;_P"-4<C_ *8>T79_<;I%,9:Q/MWBG_H
MZ?\ ^#)O_C5--_XH_P"@#I__ (,F_P#C5'(_Z8>T79_<;!&#3Q6";[Q1_P!
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M..34Z#BJT3;CFK24@)!3L4@IU( I*6FF@89HS244Q :2@FF[J '4N:9NI=U
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MKSV]Z]7U/P]I6K6$=C>6:/;Q?ZM%)39QCC&,5DV/P[\-V5RLZ6)D=3E1-(6
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MI1Y:,,A@.E $1ADC(,BD#U'-.N'SA?;H:GBF=T#/P!Z5)+<PW2!'1 XZ$=:
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M>J\)._KWHHH0'0Z0[D[2S%?3/%9FJHJW(VJ!\W8444+<"74N+&W X&*S8?\
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M0=:**8AZU*M%%(!PIU%% Q:***0!1110,*#110(2BBBF M(:** &FHVZ444
M0/3%HHJ)%1)5J&__ ./&3\/YBBBHELS2/Q(Y^7O38/\ 6445S+<ZI;&U;?=%
M6QTHHKJ6QQO<0]*KR@444F-&;.HW'@5 JC=T'Y445GU-31MQTK3C^[115P,I
$[G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
